SWP
RADX

Strategic Wealth Partners’s Radiopharm Theranostics RADX Stock Holding History

Strategic Wealth Partners’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$52 – 1575
2025
Q4 		$52 Buy
+10
New +$53 ﹤0.01% 1408

Other funds holding RADX

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Strategic Wealth Partners's RADX Position: Q1 2026 in Review

Strategic Wealth Partners sold out of Radiopharm Theranostics (RADX) in Q1 2026, closing a stake of 10 shares — an estimated $52 sold.

Strategic Wealth Partners first reported a position in RADX in Q4 2025 and held it in 1 quarter. The position peaked at $52 in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

  • Strategic Wealth Partners reported no remaining Radiopharm Theranostics position as of Q1 2026 after selling out during the quarter.
  • Strategic Wealth Partners sold 10 Radiopharm Theranostics shares in Q1 2026, an estimated $52.
  • Strategic Wealth Partners first reported a position in Radiopharm Theranostics in Q4 2025 and held it in 1 quarter.
  • Strategic Wealth Partners's Radiopharm Theranostics position peaked at $52 in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.